Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

This study reviews outcomes in patients with advanced kidney cancer (metastatic renal cell carcinoma) who received a combination of stereotactic body radiation therapy (SBRT) — high-dose targeted radiation — and an immunotherapy drug that blocks PD-1. Researchers are analyzing whether this combination triggers a broader immune response that can attack cancer throughout the body, not just where radiation was applied. **You may be eligible if...** - You are 18 or older - You have stage IV (advanced/metastatic) kidney cancer confirmed by biopsy - You have already received SBRT combined with PD-1 immunotherapy - Your cancer is measurable by standard imaging criteria **You may NOT be eligible if...** - You cannot be adequately followed up medically - You have another active cancer that is growing or requires treatment Talk to your doctor to see if this trial is right for you.